A gene mutation discovered in a small Amish community in Indiana has inspired the use of a new experimental drug for COVID-19 that reduces blood clotting, which is a primary driver of morbidity and organ damage in the disease. The first clinical trial of the drug in COVID-19 patients has just been launched at Northwestern Medicine.
